

Maristella Maggi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6738421/publications.pdf>

Version: 2024-02-01

21
papers

335
citations

840585

11
h-index

887953

17
g-index

21
all docs

21
docs citations

21
times ranked

512
citing authors

#	ARTICLE	IF	CITATIONS
1	Glutaminase activity determines cytotoxicity of l-asparaginases on most leukemia cell lines. <i>Leukemia Research</i> , 2015, 39, 757-762.	0.4	81
2	A protease-resistant <i>Escherichia coli</i> asparaginase with outstanding stability and enhanced anti-leukaemic activity in vitro. <i>Scientific Reports</i> , 2017, 7, 14479.	1.6	42
3	A new variant of phosphoglycerate kinase deficiency (p.I371K) with multiple tissue involvement: Molecular and functional characterization. <i>Molecular Genetics and Metabolism</i> , 2012, 106, 455-461.	0.5	30
4	Anti-Cancer Auto-Antibodies: Roles, Applications and Open Issues. <i>Cancers</i> , 2021, 13, 813.	1.7	27
5	Engineering of <i>Helicobacter pylori</i> L-Asparaginase: Characterization of Two Functionally Distinct Groups of Mutants. <i>PLoS ONE</i> , 2015, 10, e0117025.	1.1	25
6	Insights into human phosphoglycerate kinase 1 deficiency as a conformational disease from biochemical, biophysical, and in vitro expression analyses. <i>Journal of Inherited Metabolic Disease</i> , 2014, 37, 909-916.	1.7	22
7	The phosphoglycerate kinase 1 variants found in carcinoma cells display different catalytic activity and conformational stability compared to the native enzyme. <i>PLoS ONE</i> , 2018, 13, e0199191.	1.1	20
8	Enzymes in Metabolic Anticancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1148, 173-199.	0.8	19
9	Protein Stability, Folding and Misfolding in Human PGK1 Deficiency. <i>Biomolecules</i> , 2013, 3, 1030-1052.	1.8	15
10	Biochemistry of lipolytic enzymes secreted by <i>Penicillium solitum</i> and <i>Cladosporium cladosporioides</i> . <i>Bioscience, Biotechnology and Biochemistry</i> , 2014, 78, 245-254.	0.6	14
11	Enhanced expression and purification of camelid single domain VHH antibodies from classical inclusion bodies. <i>Protein Expression and Purification</i> , 2017, 136, 39-44.	0.6	14
12	Tackling Critical Catalytic Residues in <i>Helicobacter pylori</i> L-Asparaginase. <i>Biomolecules</i> , 2015, 5, 306-317.	1.8	8
13	High resolution structure of human apolipoprotein (a) kringle IV type 2: beyond the lysine binding site. <i>Journal of Lipid Research</i> , 2020, 61, 1687-1696.	2.0	6
14	A Targeted Catalytic Nanobody (T-CAN) with Asparaginolytic Activity. <i>Cancers</i> , 2021, 13, 5637.	1.7	4
15	Clinical Severity of PGK1 Deficiency Due To a Novel p.E120K Substitution Is Exacerbated by Co-inheritance of a Subclinical Translocation t(3;14)(q26.33;q12), Disrupting NUBPL Gene. <i>JIMD Reports</i> , 2015, 23, 55-65.	0.7	3
16	Revealing <i>Escherichia coli</i> type II l-asparaginase active site flexible loop in its open, ligand-free conformation. <i>Scientific Reports</i> , 2021, 11, 18885.	1.6	3
17	L-asparaginase: A Novel Bacterial Antigen that May Contribute to Infection Detection. <i>Annals of Clinical and Laboratory Science</i> , 2018, 48, 654-658.	0.2	1
18	Structural Aspects of <i>E. coli</i> Type II Asparaginase in Complex with Its Secondary Product L-Glutamate. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5942.	1.8	1

#	ARTICLE	IF	CITATIONS
19	Data on enhanced expression and purification of camelid single domain antibodies from Escherichia coli classical inclusion bodies. Data in Brief, 2017, 12, 132-137.	0.5	0
20	HAP1 loss in l-asparaginase resistance. Blood, 2019, 133, 2116-2118.	0.6	0
21	Abstract 3378: Glutaminase activity determines cytotoxicity of L-asparaginases on leukemia cell lines. , 2014, , .		0